Epigenetics Market: By Enzymes (DNA polymerase, Acetylases, DNA ligases, Methyltransferase, RNA ligases, Reverse Transcriptase, Others), By Instruments (Next generation sequencers, Mass spectrometers, Sonicators, qPCRs, Others), By Application (Oncology, Cardiovascular diseases, Metabolic diseases, Inflammatory diseases, Infectious diseases), By kits and Assays (Deep sequencing kit, Bisulfate conversion kit, Methyltransferase assays, Chip- seq kits, Immunoprecipitation kits, Histone assay), By End-User (Pharmaceutical and biotechnological companies, Contract research companies, Academic and Research Institutes), and Geography.

 

Epigenetics Market Size was valued at US$ 823 Million in 2020 and is projected to reach US$ 2021.73 Million at a CAGR of 13.7% by 2027 during the forecast period 2021- 2027. Epigenetics is a study of heritable changes in gene expression which involves the change in phenotype without changing genotype, which in turn affects the reading of genes by cells. Epigenetic changes are natural and regular processes but also influenced by various factors like lifestyle, environment, age and state of disease. Epigenetic modifications can manifest a common manner of cells which differentiate terminally to end up as liver cells, skin cells, brain cells etc. Epigenetic change may have more damaging effects which can lead to diseases like cancer. Systems like histone modification, non-coding RNA-associated gene silencing and DNA methylation are considered for initiation of epigenetic change sustainably. In October 2016 Episode an epigenetics data company launched SEED a novel male fertility test to evaluate epigenetic changes on DNA to detect a risk of infertility and poor embryo development. In June 2011, Cayman chemical company has adopted Genedata screener of Genedata, the company of advanced software solutions for drug discovery and life science research as a data management platform for cayman’s new epigenetic screening laboratory.